INDEVUS COMPLETES ENROLLMENT IN TRIAL FOR SANCTURA XR
Indevus Pharmaceuticals has reported that enrollment has been completed in the company's second Phase III trial for Sanctura XR for overactive bladder.
The second of the two Phase III trials is fully enrolled with over 560 patients. Both trials are 12-week, double-blind, placebo-controlled studies, evaluating the effect of Sanctura XR in reducing frequency, urgency, and incontinence episodes in patients with overactive bladder. Consistent with previous guidance, the company expects to file a new drug application with the FDA by the end of the year.